Ascentage Pharma Group International announced that it has released the clinical data of lisaftoclax (APG-2575), one of the company's key drug candidates, combined with various novel therapies in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (amyloid light-chain [AL) amyloidosis, in a Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States. This is the first data readout of lisaftoclax for the treatment of patients with R/R MM. The ASH Annual Meeting is one of the largest gatherings of the international hematology community, bringing together the most cutting-edge scientific research and latest data of investigational therapies that represent leading scientific and clinical advances in the global hematology field.

Lisaftoclax was well tolerated even when the combination dose was escalated up to 1200 mg. At the same time, the efficacy of lisaftoclaxfor patients with AL amyloidosis is also showing up. Highlights of the study presented at ASH 2023: First Report on the Effects of Lisaftoclax (APG -2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis.

Highlights of the study presented At ASH 2023: First report on the Effects of Lisaftocax (APG-25 75) in Combination with NovelTherapeutic Regimens in Patients With Relapsed or Refractory multiple Myeloma (R/R/R MM) or Immunogulin Light-Chain (Amy Loid Light-Chain [AL') Amyloidosis. Highlights: Lisaftoclax is an investigational, novel, potent, selective Bcl-2 inhibitor under clinical development for treatment of patients with hematologic malignancies or solid tumors and has shown clinical antibody benefits. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL).

Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs, 2 FTDs, and 2 Rare Pediatric Disease (RPD) Designations from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property, and the company's investigational therapies that represent leading Scientific and clinical advances in the global Hematology field.

Lisaftocax was well tolerated even when The combination dose was escalated up to 1,200 mg. At the same time.